Trimethylamine-d9 N-oxide (Synonyms: TMAO-d9) |
Catalog No.GC48206
One-Click Copy Product Info
|
An internal standard for the quantification of trimethylamine N-oxide
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1161070-49-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Trimethylamine-d9 N-oxide is intended for use as an internal standard for the quantification of trimethylamine N-oxide by GC- or LC-MS. Trimethylamine N-oxide (TMAO) is a metabolite of choline, phosphatidylcholine, and L-carnitine .1 It is formed by gut microbiota-mediated metabolism of choline, phosphatidylcholine, and L-carnitine to TMA followed by oxidation of TMA by flavin-containing monooxygenase 3 (FMO3) in the liver.1,2,3 Dietary administration of TMAO (0.12% w/w) increases renal tubulointerstitial fibrosis, collagen deposition, and Smad3 phosphorylation in mice and increases aortic lesion area in atherosclerosis-prone ApoE-/- mice.1,4 Plasma levels of TMAO are elevated in patients with chronic kidney disease and decreased in patients with active, compared with inactive, ulcerative colitis.1,2 Elevated plasma levels of TMAO are associated with increased risk of cardiovascular disease.4
1.Tang, W.H.W., Wang, Z., Kennedy, D.J., et al.Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney diseaseCirc. Res.116(3)448-455(2015) 2.Wilson, A., Teft, W.A., Morse, B.L., et al.Trimethylamine-N-oxide: A novel biomarker for the identification of inflammatory bowel diseaseDig. Dis. Sci.60(12)3620-3630(2015) 3.Zhang, L.S., and Davies, S.S.Microbial metabolism of dietary components to bioactive metabolites: Opportunities for new therapeutic interventionsGenome Med.8(1)46(2016) 4.Wang, Z., Klipfell, E., Bennett, B.J., et al.Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseNature472(7341)57-63(2011)
| Cas No. | 1161070-49-0 | SDF | |
| Sinónimos | TMAO-d9 | ||
| Canonical SMILES | O=[N](C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H] | ||
| Formula | C3D9NO | M.Wt | 84.2 |
| Solubility | H2O : 100 mg/mL (1188.07 mM; Need ultrasonic); DMSO : 100 mg/mL (1188.07 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 11.8765 mL | 59.3824 mL | 118.7648 mL |
| 5 mM | 2.3753 mL | 11.8765 mL | 23.753 mL |
| 10 mM | 1.1876 mL | 5.9382 mL | 11.8765 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)